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Background: An estimated 3.2 million patients annually develop healthcare-associated infections (HCAIs) in
Europe alone amid the major challenge of increasing antimicrobial resistance. Critically ill children warrant spe-
cific evaluation because of differences in epidemiology, causative organisms and infection sites.
Objectives: To examine the prevalence and antimicrobial susceptibility patterns of three types of HCAI in critical-
ly ill children and determine the effect on their disease course.
Materials and methods: Retrospective cohort review of critically ill children admitted to a general paediatric ICU
(PICU) at a regional academic tertiary referral centre over a 3 year period.
Results: There were 1930 admissions with a median age of 38 months. Children with HCAIs had a higher
incidence of comorbidities (74% versus 24%) and a longer median length of stay (8 days versus 3 days). We iden-
tified 26 positive isolates (blood, lower respiratory and urine) taken 48 h or more after admission. The combined
incidence was 1.34%. Hospital-acquired pneumonia accounted for 58% of HCAIs, urinary tract infections
for 31% and bloodstream infections for 11%. The majority (61.5%) of HCAIs were caused by Gram-negative
organisms. Seven isolates were resistant to antimicrobials used to treat HCAI. All of these were Gram-negative
organisms (Pseudomonas aeruginosa, Klebsiella oxytoca and Escherichia coli).
Conclusions: These data revealed a low incidence of HCAIs, 27% of which were resistant Gram-negative organ-
isms. Critically ill children with HCAIs were more likely to have comorbidities and an increased length of stay.
These factors may increasingly impact on PICU bed availability, an already limited resource.
Introduction
Healthcare-associated infections (HCAIs) are some of the most
frequent adverse outcomes in healthcare delivery. A recent point
prevalence study involving 29 EU member states found a 6%
prevalence of HCAI and estimated that 3.2 million patients de-
velop an HCAI each year.1 Global data on HCAI are limited because
of the wide variability of surveillance, diagnostic criteria, reliability
of data collection and reporting across the world. However, it is
well recognized that patients acquiring HCAIs are at increased risk
of adverse outcomes including prolonged hospital stay, mortality
risk and increased antimicrobial resistance (AMR). In addition,
HCAI and AMR are also associated with a massive financial bur-
den.2 The financial loss associated with directs costs is estimated
at e7 billion each year in Europe. In the USA the annual economic
impact was estimated at US$6.5 billion in 2004.2
AMR represents one of the greatest challenges in healthcare
and it is set to increase. From a historical perspective, antibiotic
resistance was observed in bacteria soon after antibiotics were
introduced as treatment for infections.3 As antibiotic use has
increased, so have the level and complexity of resistance mecha-
nisms developed by bacteria.4
There is increasing recognition that HCAIs are a significant prob-
lem in all groups of hospitalized patients. The most vulnerable are
the sickest patients and those at extremes of age. International
studies have highlighted differences between children and adults
in terms of epidemiology, causative organisms and infection sites.
However, there are few data regarding the critically ill paediatric
population, where antimicrobial use is widespread.5 The few stud-
ies in this area have shown that the spectrum of HCAI identified
in paediatric ICUs (PICUs) differs from other inpatient paediatric
settings and warrants specific evaluation.
A recent point prevalence study showed that the incidence
of HCAI was higher in PICUs than in any other paediatric
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department. Furthermore, there was a significant amount of AMR
in both Gram-positive and Gram-negative bacterial isolates.6
Within this context, increasing numbers of children with life-
limiting conditions are being admitted to PICUs and now account
for the majority of bed days on PICUs. Children in this population
have complex care needs and frequently attend a variety of
healthcare settings.7
PHE recently reported that the greatest threat of AMR is
from Gram-negative bacteria, with Escherichia coli, Klebsiella
pneumoniae and Pseudomonas aeruginosa accounting for 72% of
all Gram-negative bloodstream infections in the UK.8 Resistant
strains of staphylococci and enterococci indicate that Gram-
positive organisms are also of significant concern.4
Resistance may result from de novo mutation of genes or
horizontal transfer of genetic elements from other organisms
carrying resistance genes leading to a variety of enzymatic- and
non-enzymatic-mediated pathways.9
Enzyme-mediated resistance includes expression of enzymes
that destroy antimicrobial drugs, efflux systems that prevent drugs
from reaching intracellular target sites, modification of target sites,
or alternative metabolic pathways that bypass the action of
antimicrobials.4 The effectiveness of resistance mechanisms is
demonstrated by the rapid spread of resistant strains. In add-
ition to the rise in ESBL-producing Enterobacteriaceae and
AmpC-producing organisms, carbapenemase-producing strains
have emerged as a result of enzymes such as Verona Integron-
Mediated (VIM) and New Delhi-type MBLs (NDM), OXA-48 and
K. pneumoniae carbapenemase (KPC). This diversity in mecha-
nisms of AMR is a cause of major concern, particularly for
patients in ICUs.9
In this study, we examined the prevalence and epidemiology of
HCAI in critically ill children. To this end we surveyed the cultures of
blood, urine and endotracheal secretions taken after 48 h of ad-
mission to the PICU to identify potential HCAI. We examined
whether antimicrobial susceptibility patterns of the causative
organisms affected the course of their disease.
Methods
We carried out a retrospective review of children admitted to the PICU at a
large regional academic tertiary referral centre over a 3 year period be-
tween November 2014 and October 2017.
We identified all patients admitted to the PICU and interrogated the
electronic patient record to identify all patients with positive microbiological
samples (blood, urine or endotracheal secretions) collected following ad-
mission to the PICU. We collected demographic information and reviewed
each patient record to identify clinical, radiological and microbiological fea-
tures (as relevant) that were consistent with bloodstream infection, urinary
tract infection or lower respiratory tract infection.
Inclusion criteria were: (i) children and young people aged under
16 years admitted to the PICU at Addenbrooke’s Hospital between
1 November 2014 and 31 October 2017, inclusive; (ii) hospital admission of
48 h or more; and (iii) positive culture of blood, urine, sputum or bronchoal-
veolar lavage samples taken 48 h or more after admission and associated
clinical features of bloodstream infection, urinary tract infection or lower
respiratory tract infection, respectively.10
Exclusion criteria were: (i) bloodstream, urinary tract or lower respiratory
tract infections that began before, or at the time of, admission; (ii) coloniza-
tion with organisms without adverse clinical features; and (iii) children with
clinical features of bloodstream infection, urinary tract infection, or lower
respiratory tract infection but with negative culture of blood, urine and
endotracheal secretion samples, respectively.
We excluded duplicate samples from the same hospital-acquired infec-
tion that showed identical results but included those from which different
organisms were isolated.
Finally, we reviewed the susceptibility patterns of the organisms
identified. At the time of the study, the empirical antibiotic treatment for
suspected HCAI was either piperacillin/tazobactam and gentamicin in com-
bination, or meropenem alone. Departmental guidelines recommended
discussion with a microbiologist before selecting antimicrobials for HCAI
in patients with allergy to penicillin or cephalosporins. We specifically
sought to identify isolates resistant to these antibiotics. We also sought
to identify the incidence of MRSA, ESBL-producing organisms, VRE and
carbapenemase-producing Enterobacteriaceae. The process by which
HCAIs were identified is illustrated in Figure 1.
Descriptive data are presented as numbers and percentages. Means
and SD or medians and IQR are used as appropriate.
Ethics
The study was categorized and approved as a service evaluation by our in-
stitution. Ethics committee approval and patient consent were not required
for this retrospective study.
Results
During the 3 year period studied there was a total of 1930 admis-
sions to the PICU, of which 44% were female. Median age was
38 months (10–118). Demographic and diagnostic data are out-
lined in Table 1. Respiratory conditions accounted for the largest
primary diagnostic group, followed by surgical conditions.
The cultures of blood, respiratory secretions and urine taken at
least 48 h after PICU admission yielded a total of 26 positive iso-
lates from 23 different patients. One patient had positive cultures
from endotracheal secretions on three different admissions. In
another patient two different organisms were isolated from urine
culture during the same illness.
The combined incidence of the three HCAIs was 1.34%. The
highest numbers of HCAIs were pneumonias (58%), followed by
urinary tract infections (31%).
Almost one quarter of all children admitted to the PICU had one
or more comorbidities. Seventy-four percent of patients in whom
an HCAI was identified had one or more significant comorbidities.
Forty percent of patients with HCAI had documentation of a previ-
ous PICU or neonatal ICU (NICU) admission. The median length of
stay (LOS) for all patients admitted to PICU within the study period
was 3 days (2–6). The median LOS was 8 days (5.25–10) for
patients with HCAI. These data are shown in Figure 2.
All cases of hospital-acquired pneumonia (HAP) were associ-
ated with endotracheal tubes. The majority of bloodstream infec-
tions and urinary tract infections were associated with central
venous and urinary catheters, respectively, as shown in Figure 3.
A broad distribution of organisms was identified in patients
with HCAI, of which 16 (61.5%) were Gram-negative organisms
and 10 (38.5%) were Gram-positive organisms. This is shown in
Table 2.
There was marked variation in the organisms identified in dif-
ferent types of HCAI. All three hospital-acquired bloodstream
infections were with Gram-positive organisms [Enterococcus
faecalis (1), Enterococcus faecium (1) and Staphylococcus epidermi-
dis (1)]. Gram-negative organisms, particularly Enterobacteriaceae
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and Pseudomonas were dominant among the 15 patients with
HAP. The eight urinary tract infections were due to E. faecalis (four
isolates) and E. coli (four isolates).
Our review of the susceptibility pattern of the 26 hospital-
associated isolates identified few organisms with significant
resistance. Overall there were seven isolates with resistance to
antimicrobials commonly used as treatment for HCAI. All were
Gram-negative organisms: three P. aeruginosa, two Klebsiella oxy-
toca and two E. coli. Five of the seven resistant isolates were from
sputum and two were obtained from urine. We looked specifically
Figure 1. Flowsheet for identifying HCAIs. BAL, bronchoalveolar lavage.
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at resistance to piperacillin/tazobactam, ceftazidime, glycopeptides,
aminoglycosides and carbapenems. In relation to Pseudomonas we
also looked at resistance to ciprofloxacin.
Among the five endotracheal isolates with resistance, there
was one K. oxytoca resistant to piperacillin/tazobactam (suscep-
tible to ceftazidime) and one K. oxytoca resistant to ceftazidime
(susceptible to piperacillin/tazobactam). Among the three endo-
tracheal isolates with resistant P. aeruginosa, one was resistant to
ciprofloxacin and two were resistant to carbapenems. Although
an ESBL-producing K. pneumoniae was isolated from one
endotracheal sample, both disc testing and determination of MIC
demonstrated susceptibility to gentamicin and meropenem. E. coli
resistant to gentamicin was isolated from two urine samples. Both
isolates were susceptible to amikacin. These data are shown in
Table 2.
There were no resistant organisms identified among hospital-
acquired bloodstream infections. The three Gram-positive isolates
from blood cultures were susceptible to either vancomycin or teico-
planin. There were no hospital-acquired infections with MRSA, VRE
or carbapenemase-producing Enterobacteriaceae in our study.
Discussion
Incidence of HCAIs
The primary focus of this study was the incidence of healthcare-
associated bloodstream, respiratory and urinary tract infections
and the resistance patterns of their causative bacteria. Our data
showed an incidence of HCAI of 1.34%. This is lower than reported
in previous studies.
Richards et al.5 reported a mean overall infection rate of 6.1% in
their prospective study of 61 PICUs published in 1999. Raymond
et al.11 reported an overall incidence of 2.4% across all paediatric
wards and an alarmingly high incidence of 23.6% across five PICUs
in their European multi-centre prospective study published in
2000.
A recent point prevalence study of HCAIs in paediatric patients
by the ECDC reported an overall prevalence of 4.2% across a var-
iety of paediatric acute care facilities. They also found the highest
prevalence in PICUs at 15.5%.6
It is important to note differences in methodology when inter-
preting these data. Positive microbiology was a requirement
for inclusion in our study. Furthermore, our focus was on blood-
stream infections, pneumonias and urinary tract infections, which
accounted for the overwhelming majority of infections in the previ-
ous studies (80% in the 2000 study and over 70% in the 2017
study). Other studies included surgical site wound infections,
gastrointestinal infections and viral and fungal infections, which
were not included in our study. In light of the low incidence of
HCAI, we suggest that inclusion of other infections would be un-
likely to alter our results significantly. Furthermore, the diagnostic
criteria in the earlier studies appear more liberal than the criteria
we employed.
Despite the limitations described above, the low incidence
we identified may be associated with greater recognition of the
risks of HCAI and AMR. Although there are no baseline data for
our PICU from previous years for comparison, successive years
have seen implementation of infection control policies. These
range from improvements in screening and surveillance, strict
isolation protocols to prevent the spread of infection and
formalized antimicrobial stewardship embedded through multi-
disciplinary rounds.
Despite these examples of good practice, there remains an
ongoing need to reinforce and re-evaluate established preventa-
tive infection control measures such as hand hygiene, isolation,
maintenance of asepsis during invasive procedures and timely
removal of invasive devices.
Comorbidities
Within the cohort of patients admitted to our PICU over the 3 year
period, just under one quarter (24.4%) were noted to have at least
one comorbidity. In contrast, over two-thirds (74%) of patients
with HCAIs had one or more comorbidities. Children with comor-
bidities are more likely to have multiple admissions to PICUs, which
in turn could result in increased antibiotic exposure, with implica-
tions for AMR. In the context of the increasing proportion of PICU
admissions of children with complex and life-limiting conditions,
this is a subject that requires further analysis.
Table 1. Demographic and diagnostic data for all patients
Category Value
Total PICU admissions November
2014–October 2017
1930
Female, n (%) 847 (44)
Age range 0 days–18 years
4 months
Median (IQR) age (months) 38 (10–118)










blood/lymphatic (non-oncology) 20 (1)
musculoskeletal 7 (0.4)
other 31 (1.6)
Mechanical ventilation, n (%) 735 (38)
Median (IQR) length of mechanical venti-
lation (days)
4 (2–6)
Comorbidities in all patients, n (%) 470 (24.4)
Comorbidities in patients with HCAI, n (%) 17 (74)
Median (IQR) LOS for all patients (days) 3 (2–6)
Median (IQR) LOS for patients without
HCAI (days)
3 (2–5.5)
Median (IQR) LOS for patients with HCAI
(days)
8 (5.25–10)
Median (IQR) LOS for patients with resist-
ant HCAI (days)
7.5 (4.5–10)




In our study the distribution of HCAIs was different from previously
reported studies. We found respiratory tract infections (57.7%)
to be most common, followed by urinary tract infections (30.8%)
then bloodstream infections (11.5%). Raymond et al.11 and
Richards et al.5 reported that the most commonly identified HCAIs
in PICUs were bloodstream infections followed by lower respiratory
tract infections and urinary tract infections. Zingg et al.6 did not
specifically describe the distribution of infections in PICUs but iden-
tified bloodstream infections as the most common, followed by
lower respiratory tract infections, gastrointestinal infections, upper
respiratory tract infections and urinary tract infections.6
The increased LOS in patients with HCAI (median of 8 days
compared with 3 days) highlights the significant impact of HCAI
on patient outcomes. Although the number of episodes of HCAI
in our study was small (n"26), an increased LOS has a signifi-
cant impact on costs and reduces PICU bed availability, the ef-
fect of which is more pronounced at times of seasonal high
demand.
Organisms and resistance
In our study, Gram-negative organisms accounted for the majority
(61.5%) of all isolates and accounted for all of the organisms
with resistance to commonly used antimicrobials. This reflects
the expression of concern from PHE8 about the threat posed by
Gram-negative organisms and alerts us to the potential for these
bacteria to evolve mechanisms of resistance and potentially evade
treatment with all current antimicrobials.12
As outlined earlier, although some bacteria have innate
resistance to certain classes of antibiotics, of greater concern is the
Figure 3. Indwelling devices in patients with HCAI. BSI, bloodstream in-
fection; UTI, urinary tract infection.
Figure 2. Median LOS for all groups.
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ability of initially susceptible bacteria to acquire resistance through
mutations and selection pressures or by horizontal transfer of
genetic material. These mechanisms have enabled organisms to
develop MDR, a process that has been demonstrated in vivo
with the demonstration of evolving resistance patterns of bacterial
populations during courses of antibiotic treatment.4
Resistance to empirical antibiotics has been associated with
increased mortality in patients with Staphylococcus aureus, CoNS,
enterococci, Enterobacter spp., P. aeruginosa, K. pneumoniae and
E. coli. Though we did not identify any resistant hospital-acquired
bloodstream infections, the existence of resistant Gram-negative
isolates from sputum and urine samples demands that we antici-
pate the emergence of such invasive infections.
Wider context of HCAI and AMR in our institution
Our PICU is within a large regional academic centre with over 1000
inpatient beds. In the year 2016–17 the Infection Prevention and
Control (IPC) indices ranked around the average for NHS acute
trusts in England.13
Our findings on HCAI and AMR in the PICU should be considered
within the wider context of HCAI and AMR at our institution.
According to PHE AMR local indicators, cases of HCAI in our institu-
tion were generally lower than the average for England in 2017.
Hospital-onset cases of Klebsiella spp., P. aeruginosa and MRSA
were all within the lowest or second lowest quintile in England.
However, cases of hospital-onset E. coli ranged from the middle to
the highest quintile in England for 2017.13
Following a review of the cases of MRSA, improvements to proc-
esses and practices have been implemented. This includes routine
screening of inpatients staying longer than 40 days.14
The reported indicators of AMR for our institution during
this period were more variable. The rolling average proportion
of gentamicin-resistant E. coli was in the middle quintile.
The equivalent indicators for ciprofloxacin- and piperacillin/
tazobactam-resistant E. coli were in the highest and second high-
est quintiles in England respectively.13 There were 17 cases of
carbapenemase-producing Enterobacteriaceae in our institution in
the financial year 2016–17. Comparative data for carbapenem re-
sistance was not available at the time of writing. During this period
our institution implemented national guidance for the identifica-
tion and management of the most resistant microorganisms.14
In contrast with the hospital setting, the development of AMR
after antibiotic treatment has been well described in primary care. A
systemic review by Costelloe et al.15 found that individual patients
prescribed antibiotics for respiratory or urinary tract infections devel-
oped AMR, with the effect greatest in the month immediately after
treatment and persisting for up to 12 months.15 In light of the small
numbers of resistant isolates in our study, such studies examining
AMR at the level of the individual patient are of particular interest for
the high-quality evidence linking antibiotic use to AMR.
Allowing for the many differences between community and
ICU care, the residual effect holds the potential to influence
a more tailored approach to antimicrobial therapy in the PICU.
There is a case for more considered use of antibiotics generally,
particularly for those children with multiple PICU admissions,
exposed to multiple courses of antibiotics.
Limitations
This study was a retrospective cohort review of patients with
HCAIs. The limitations of this approach are that the methods of
Table 2. Organisms and AMR in patients with HCAI
Type of HCAI Value, n (%)






E. faecalis 5 (19.2)
E. faecium 2 (7.7)
S. aureus 2 (7.7)
S. epidermidis 1 (3.8)
Gram-negative organisms 16 (61.5)
P. aeruginosa 5 (19.2)
E. coli 4 (15.4)
K. oxytoca 3 (11.5)
Haemophilus influenzae 2 (7.7)
Citrobacter freundii 1 (3.8)
K. pneumoniae 1 (3.8)
Type of HCAI Organism Resistance
bloodstream infection E. faecium nil
bloodstream infection S. epidermidis nil
bloodstream infection E. faecalis nil
pneumonia C. freundii nil
pneumonia E. faecium nil
pneumonia H. influenzae nil
pneumonia H. influenzae nil
pneumonia K. oxytoca nil
pneumonia K. oxytoca ceftazidime





pneumonia P. aeruginosa ciprofloxacin
pneumonia P. aeruginosa ertapenem
pneumonia P. aeruginosa imipenem
pneumonia P. aeruginosa nil
pneumonia P. aeruginosa nil
pneumonia S. aureus nil
pneumonia S. aureus nil
UTI E. faecalis nil
UTI E. faecalis nil
UTI E. faecalis nil
UTI E. faecalis nil
UTI E. coli nil
UTI E. coli nil
UTI E. coli gentamicin
UTI E. coli gentamicin
UTI, urinary tract infection.
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sampling, investigation and documentation in the electronic pa-
tient record were not designed for the purposes of the study. In a
prospective study, knowledge of these criteria may increase the
vigilance for diagnostic observations and investigations docu-
mented, resulting in fewer missed cases compared with a retro-
spective study. Retrospective cohort reviews are less useful for
drawing associations between risk factors such as central venous
catheters, compared with prospective studies.16
Our study was limited to positive cultures obtained from the
bloodstream, endotracheal secretions or urine. The study did not in-
clude infections of other body sites nor viral or fungal infections.
The CDC definition of certain types of HCAI, for example
urinary tract infection, permits a diagnosis to be made without an
organism being cultured. In contrast, positive microbiology was a
requirement in our study. This excluded cases that may have been
considered as HCAI according to the CDC definition.
Conclusions
The incidence of HCAI in our study (1.34%) is significantly lower
than the lowest previously reported incidence of HCAIs, both in the
paediatric intensive care setting and in the wider healthcare con-
text. Critically ill children with HCAI were more likely to have
comorbidities and an increased LOS. Among the HCAI identified,
30% were resistant Gram-negative organisms. The risk posed
by HCAI and AMR is likely to increase with imprudent use of antimi-
crobials, the increasing number of children who have repeated
admissions to inpatient care facilities and international travel from
areas with high rates of AMR.
The challenges of HCAI and AMR may increasingly impact bed
availability and other health resources. They demand a continuous
formal programme of surveillance and rigorous infection control
measures across all settings but particularly in areas of high risk
such as the PICU.12
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9 Ruppé É, Woerther PL, Barbier F. Mechanisms of antimicrobial resistance in
Gram-negative bacilli. Ann Intensive Care 2015; 5: 21.
10 ECDC. Healthcare-Associated Infections Acquired in Intensive Care
Units—Annual Epidemiological Report 2016 [2014 data]. 2017. https://ecdc.
europa.eu/en/publications-data/infections-acquired-intensive-care-units-
annual-report-2016.
11 Raymond J, Aujard Y. Nosocomial infections in pediatric patients: a
European, multicenter prospective study. European Study Group. Infect
Control Hosp Epidemiol 2000; 21: 260–3.
12 Magiorakos A, Srinivasan A, Carey RB et al. Multidrug-resistant, extensive-
ly drug-resistant and pandrug-resistant bacteria: an international expert pro-
posal for interim standard definitions for acquired resistance. Clin Microbiol
Infect 2012; 18: 268–81.




14 Cambridge University Hospitals NHS Foundation Trust. Infection Control
Annual Report 2016/2017. 2017. https://www.cuh.nhs.uk/sites/default/files/
Infection Control Annual Report 2016-17.pdf.
15 Costelloe C, Metcalfe C, Lovering A et al. Effect of antibiotic prescribing
in primary care on antimicrobial resistance in individual patients: systematic
review and meta-analysis. Br Med J 2010; 340: 2096.
16 Sedgwick P. Retrospective cohort studies: advantages and disadvan-
tages. BMJ 2014; 348: 1072.
Healthcare-associated bacterial infections in the PICU JAR
7 of 7
